Story · Medicine & Biotech

Aakash Desai: Izalontamab Brengitecan Shows Significant Survival Benefits in ESCC

1 outlet · first reported by OncoDaily on

Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X: “PANKU-Esophagus01 phase 3 (JAMA): EGFRxHER3 bsADC iza-bren vs chemo, 2L ESCC (n=497) mPFS 4.17 vs 1.97 mo, HR 0.50 (OncoDaily)

Coverage, in order

  1. OncoDaily obscure randomized trialpeer-reviewed
    Aakash Desai: Izalontamab Brengitecan Shows Significant Survival Benefits in ESCC

    Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X: “PANKU-Esophagus01 phase 3 (JAMA): EGFRxHER3 bsADC iza-bren vs chemo, 2L ESCC (n=497) mPFS 4.17 vs 1.97 mo, HR 0.50

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.